EMBO Molecular Medicine (Feb 2024)

Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilans

  • Sailan Wang,
  • Pernilla Nikamo,
  • Leena Laasonen,
  • Bjorn Gudbjornsson,
  • Leif Ejstrup,
  • Lars Iversen,
  • Ulla Lindqvist,
  • Jessica J Alm,
  • Jesper Eisfeldt,
  • Xiaowei Zheng,
  • Sergiu-Bogdan Catrina,
  • Fulya Taylan,
  • Raquel Vaz,
  • Mona Ståhle,
  • Isabel Tapia-Paez

DOI
https://doi.org/10.1038/s44321-024-00035-z
Journal volume & issue
Vol. 16, no. 3
pp. 596 – 615

Abstract

Read online

Abstract Psoriatic arthritis mutilans (PAM) is the rarest and most severe form of psoriatic arthritis, characterized by erosions of the small joints and osteolysis leading to joint disruption. Despite its severity, the underlying mechanisms are unknown, and no susceptibility genes have hitherto been identified. We aimed to investigate the genetic basis of PAM by performing massive parallel sequencing in sixty-one patients from the PAM Nordic cohort. We found rare variants in the NADPH oxidase 4 (NOX4) in four patients. In silico predictions show that the identified variants are potentially damaging. NOXs are the only enzymes producing reactive oxygen species (ROS). NOX4 is specifically involved in the differentiation of osteoclasts, the cells implicated in bone resorption. Functional follow-up studies using cell culture, zebrafish models, and measurement of ROS in patients uncovered that these NOX4 variants increase ROS levels both in vitro and in vivo. We propose NOX4 as the first candidate susceptibility gene for PAM. Our study links high levels of ROS caused by NOX4 variants to the development of PAM, offering a potential therapeutic target.

Keywords